Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 4Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Mesothelioma 1Fallopian Tube Neoplasms 1Extensive Stage Lung Small Cell Carcinoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Ovarian Cancer 1

Interventions

talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Advanced Ovarian Cancer × talazoparib × Clear all
NCT01989546 2021-02-23

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
9 enrolled 11 charts
BreastGynecologicOther solid neoplasm

Advanced Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡